Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Sobrero

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2009
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trialsDaniel Sargent, Alberto Sobrero, Axel Grothey, et al.
Clinical Colorectal Cancer|April 2, 2018
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program StudyAlessandro Pastorino, Maria Di Bartolomeo, Evaristo Maiello, et al.
The Lancet. Oncology|April 21, 2019
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trialCathy Eng, Tae Won Kim, Johanna Bendell, et al.
European Journal of Cancer (Oxford, England : 1990)|September 4, 2007
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment GroupBernard Nordlinger, Eric Van Cutsem, Philippe Rougier, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2013
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancerDaniela Fenoglio, Paolo Traverso, Alessia Parodi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 6, 2013
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II studyStefano Cascinu, Rossana Berardi, Alberto Sobrero, et al.
Oncotarget|September 24, 2015
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenibLuca Faloppi, Maristella Bianconi, Riccardo Giampieri, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2015
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trialGuillem Argilés, Mark P Saunders, Fernando Rivera, et al.
Arthritis Care & Research|October 27, 2025
Building Consensus on the Essential Elements of the Musculoskeletal Physical Examination During Rheumatology Telehealth EncountersLisa Zickuhr, Alberto Sobrero, Daniel Albert, et al.
The Lancet. Oncology|December 3, 2020
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trialsThierry André, Jeffrey Meyerhardt, Timothy Iveson, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2009
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trialsDaniel Sargent, Alberto Sobrero, Axel Grothey, et al.
Clinical Colorectal Cancer|April 2, 2018
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program StudyAlessandro Pastorino, Maria Di Bartolomeo, Evaristo Maiello, et al.
The Lancet. Oncology|April 21, 2019
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trialCathy Eng, Tae Won Kim, Johanna Bendell, et al.
European Journal of Cancer (Oxford, England : 1990)|September 4, 2007
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment GroupBernard Nordlinger, Eric Van Cutsem, Philippe Rougier, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2013
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancerDaniela Fenoglio, Paolo Traverso, Alessia Parodi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 6, 2013
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II studyStefano Cascinu, Rossana Berardi, Alberto Sobrero, et al.
Oncotarget|September 24, 2015
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenibLuca Faloppi, Maristella Bianconi, Riccardo Giampieri, et al.
European Journal of Cancer (Oxford, England : 1990)|March 31, 2015
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trialGuillem Argilés, Mark P Saunders, Fernando Rivera, et al.
Arthritis Care & Research|October 27, 2025
Building Consensus on the Essential Elements of the Musculoskeletal Physical Examination During Rheumatology Telehealth EncountersLisa Zickuhr, Alberto Sobrero, Daniel Albert, et al.
The Lancet. Oncology|December 3, 2020
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trialsThierry André, Jeffrey Meyerhardt, Timothy Iveson, et al.
Pageof 8